CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −199 | $65.51 | $13K | 20,975 |
| 2026-05-19 | ROBIN HOWARD W President & CEO | Sale | −444 | $65.51 | $29K | 75,045 |
| 2026-02-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −180 | $73.00 | $13K | 21,174 |
| 2026-02-18 | ROBIN HOWARD W President & CEO | Sale | −423 | $73.00 | $31K | 75,489 |
| 2026-01-20 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −3,867 | $35.67 | $138K | 21,354 |
| 2025-12-22 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +6,250 | 25,221 | ||
| 2025-12-22 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +25,000 | 25,000 | ||
| 2025-12-22 | ROBIN HOWARD W President & CEO | Grant or award | +21,667 | 75,912 | ||
| 2025-12-22 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +86,667 | 86,667 | ||
| 2025-11-25 | Zalevsky Jonathan Chief R&D Officer | Sale | −1,157 | $54.28 | $63K | 18,971 |
| 2025-11-25 | Wilson Mark Andrew Chief Legal Officer | Sale | −630 | $54.28 | $34K | 21,585 |
| 2025-11-25 | ROBIN HOWARD W President & CEO | Sale | −2,207 | $54.28 | $120K | 54,245 |
| 2025-11-21 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +2,666 | 20,128 | ||
| 2025-11-21 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +4,766 | 4,766 | ||
| 2025-11-21 | Wilson Mark Andrew Chief Legal Officer | Grant or award | +1,903 | 22,215 | ||
| 2025-11-21 | Wilson Mark Andrew Chief Legal Officer | Grant or award · Stock Option | +3,400 | 3,400 | ||
| 2025-11-21 | ROBIN HOWARD W President & CEO | Grant or award | +7,110 | 56,452 | ||
| 2025-11-21 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +12,170 | 12,170 | ||
| 2025-09-30 | WHITFIELD ROY A Director | Grant or award · Stock Option | +8,000 | 8,000 | ||
| 2025-09-30 | GREER R SCOTT Director | Grant or award · Stock Option | +8,000 | 8,000 |
Page 2 of 18 · 355 trades